Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion (INFERRCT)
Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion SUBTITLE Prevention of Cardiovascular Death, Heart Failure Events and Deterioration in Quality of Life With INtravenous FERRic Carboxymaltose in Iron Deficient Patients With Recent Myocardial Infarction
Sponsor: Wroclaw Medical University
Listed as NCT05759078, this PHASE4 trial focuses on Myocardial Infarction, Acute and remains actively recruiting participants. Sponsored by Wroclaw Medical University, it has been updated 7 times since 2022, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE4
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE4
-
Sep 2024 — Aug 2025 [monthly]
Recruiting PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE4
-
Oct 2023 — Jul 2024 [monthly]
Recruiting PHASE4
▶ Show 2 earlier versions
-
Jul 2023 — Oct 2023 [monthly]
Recruiting PHASE4
-
Apr 2023 — Jul 2023 [monthly]
Recruiting PHASE4
First recorded
Sep 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Wroclaw Medical University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bielsko-Biala, Poland , Bydgoszcz, Poland , Chrzanów, Poland , Gdansk, Poland , Gorlice, Poland , Grudziądz, Poland , Jarosław, Poland , Kluczbork, Poland , Krakow, Poland , Kraśnik, Poland and 25 more locations